PNT — POINT Biopharma Global Income Statement
0.000.00%
HealthcareSpeculativeMid Cap
- $1.33bn
- $998.03m
- $226.58m
Annual income statement for POINT Biopharma Global, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Revenue | ||||
Total Revenue | 0 | 0 | 0 | 227 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Total Operating Expenses | 0.009 | 13.1 | 45.5 | 101 |
Operating Profit | -0.009 | -13.1 | -45.5 | 126 |
Total Net Non Operating Interest Income / Expense | ||||
Net Income Before Taxes | -0.009 | -13.3 | -45.6 | 130 |
Provision for Income Taxes | ||||
Net Income After Taxes | -0.009 | -13.4 | -45.9 | 98.3 |
Net Income Before Extraordinary Items | ||||
Net Income | -0.009 | -13.4 | -45.9 | 98.3 |
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -0.009 | -13.4 | -45.9 | 98.3 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0 | -0.148 | -0.622 | 1.02 |